We market a wide range of generics, specialty products and manufacture controlled substances in Australia. The company markets oral formulations, technologically complex injectables/delivery systems and manufactures poppy-derived opiate raw materials that are primarily used in the manufacture of analgesics. Products are manufactured to meet the stringent standards of the Australian Therapeutic Goods Administration (TGA).
Globally, our vertically integrated operations including manufacturing of Active Pharmaceutical Ingredients (APIs) and Finished Dosage formulations, together with robust R&D capabilities, enable us to maintain strict control over the quality and cost of our marketed products.
We provide high-quality, affordable medicines trusted by healthcare professionals and patients in over 150 countries of the world. Our global presence is supported by 45 manufacturing facilities across 5 continents. We have a multi-cultural workforce comprising more than 30,000 employees of over 50 nationalities.